Joint Development and Exclusive Sales Partnership with Kyorin Pharmaceutical for an Otolaryngology Therapeutic App
First written in FY2023-Q1. 10 of 16 entries say "Advanced", first in FY2023-Q2. Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「For the tinnitus treatment app being jointly developed with KYORIN Pharmaceutical Co.,Ltd., the company began a confirmatory study and received a ¥240 million milestone payment upon the first subject beginning to use the app.」
The company reported specific development progress in its joint research and development and sales partnership with KYORIN Pharmaceutical, namely the start of a confirmatory study following specified clinical research and the start of use by the first subject. - FY2026-H1AdvancedAnnual report
「In light of the results of the specified clinical research study, we entered into a memorandum of understanding to expand our role in the research and development of the app and after its sale, resulting in an increase in milestone payments and royalties based on sales.」
Under the joint development and sales partnership with Kyorin Pharmaceutical for the tinnitus treatment app, the company entered into a memorandum of understanding in light of the results of the specified clinical research study, expanding its role and increasing milestone payments and royalties. - FY2025AdvancedAnnual report
「In November 2022, we entered into an agreement with Kyorin Pharmaceutical Co., Ltd. concerning the joint research and development and sale of a treatment app in the otolaryngology field, with the aim of providing a new treatment option for tinnitus. The specified clinical research study (Note 21) has now been completed.」
The company reported concrete development progress under the joint research, development and sales partnership with Kyorin Pharmaceutical, namely completion of the specified clinical research study. - FY2025-H1RestatedAnnual report
「The specified clinical research study for the tinnitus treatment app initiated through the joint development with Kyorin Pharmaceutical Co., Ltd. is also using SUSMED SourceDataSync®.」
The company continues its joint development and sales partnership with Kyorin Pharmaceutical for the tinnitus treatment app and the use of its own system in the specified clinical research study. - FY2024-Q3RestatedAnnual report
「The specified clinical research study for the tinnitus treatment app initiated through the joint development with Kyorin Pharmaceutical Co., Ltd. is also using SUSMED SourceDataSync®.」
The company’s system continues to be used in the specified clinical research study under the joint development and sales partnership with Kyorin Pharmaceutical for the tinnitus treatment app. - FY2024-Q2RestatedAnnual report
「The specified clinical research study for the tinnitus treatment app initiated through the joint development with Kyorin Pharmaceutical Co., Ltd. is also using SUSMED SourceDataSync®.」
Under the joint development and sales partnership with Kyorin Pharmaceutical for the tinnitus treatment app, the specified clinical research study has begun and the company’s system continues to be used in the clinical research. - FY2024-Q1AdvancedAnnual report
「The specified clinical research study for the tinnitus treatment app jointly developed with Kyorin Pharmaceutical Co., Ltd. has begun.」
The company reported the start of the specified clinical research study under the joint research, development and sales partnership with Kyorin Pharmaceutical for the tinnitus treatment app, as well as the achievement of a development milestone as a subsequent event. - FY2023RestatedAnnual report
「In November 2022, we entered into an agreement with Kyorin Pharmaceutical Co., Ltd. concerning the joint research and development and sale of a treatment app in the otolaryngology field, with the aim of providing a new treatment option for tinnitus, and began developing the treatment app.」
The company continues to report the joint research, development and sales partnership with Kyorin Pharmaceutical for the tinnitus treatment app, as well as the start of development. - FY2023-Q3RestatedAnnual report
「In November 2022, under an agreement with Kyorin Pharmaceutical Co., Ltd. concerning the joint research and development and sale of a therapeutic app for tinnitus, the Company received an upfront contractual payment of ¥100 million. It expects to receive total milestone payments of up to ¥600 million depending on future development progress and other factors, as well as royalties based on sales after product launch.」
The framework for the development and sales partnership with Kyorin Pharmaceutical for the tinnitus treatment app remains in place following receipt of the upfront payment. - FY2023-Q2AdvancedAnnual report
「In November 2022, we received an upfront payment of ¥100 million under the agreement entered into with Kyorin Pharmaceutical Co., Ltd. concerning the joint research and development and sale of a treatment app in the otolaryngology field.」
The company reported concrete progress under the joint research, development and sales agreement with Kyorin Pharmaceutical, namely receipt of the ¥100 million upfront payment following execution of the agreement. - FY2023-Q1First statedAnnual report
「The two companies aim to provide new treatment options in the otolaryngology field and contribute to the advancement of healthcare by combining Kyorin Pharmaceutical’s knowledge of disease areas, clinical development capabilities and sales capabilities with our treatment-app development platform, systems related to conducting clinical trials, and expertise in treatment-app research and development.」
On 9 November 2022, the company entered into a joint research, development and sales agreement with Kyorin Pharmaceutical, establishing a framework under which Kyorin Pharmaceutical would obtain exclusive sales rights in Japan. The agreement provided for an upfront payment of ¥100 million, milestone payments of ¥600 million based on development progress, and royalties after launch.